血红蛋白病
血红蛋白变体
毛细管电泳
复合杂合度
血红蛋白
表型
β地中海贫血
遗传学
分子生物学
生物
医学
地中海贫血
基因
内科学
溶血性贫血
作者
Victoria Higgins,Lauren MacNeil,Iveta Sosova,Ross Ridsdale,Aisha Bruce,Davor Brinc,David Waltregny,J. Rara,Pierre Bordeleau,Mathew P. Estey,Michelle Parker,O.Z. Ismail,T. Agbor
标识
DOI:10.1016/j.clinbiochem.2023.110589
摘要
Hemoglobinopathies include thalassemia syndromes, where production of one or more globin subunits of hemoglobin (Hb) is reduced, and structural Hb variants. Over 1000 disorders of Hb synthesis and/or structure have been identified and characterized, with phenotypes ranging from having severe clinical manifestations to clinically silent. Various analytical methods are used to phenotypically detect Hb variants. However, molecular genetic analysis is a more definitive method for Hb variant identification.Here, we report a case of a 23-month-old male with results from capillary electrophoresis, gel electrophoresis (acid and alkaline), and high-performance liquid chromatography most consistent with HbS trait. Specifically, capillary electrophoresis showed slightly elevated HbF and HbA2, HbA of 39.4% and HbS of 48.5%. The HbS percentage was consistently higher than expected (typically 30-40%) for HbS trait with no concurrent thalassemic indices. The patient has not experienced any clinical complications due to the hemoglobinopathy and he is thriving.Molecular genetic analysis revealed the presence of compound heterozygosity for HbS and Hb Olupona. Hb Olupona is an extremely rare beta-chain variant that appears as HbA on all three common methods used for phenotypic Hb analysis. When the fractional concentration of Hb variants is unusual, more definitive methods should be used, such as mass spectrometry or molecular genetic testing. In this case, incorrectly reporting this result as HbS trait is unlikely to have a significant clinical impact, as current evidence suggests Hb Olupona is not a clinically significant variant.
科研通智能强力驱动
Strongly Powered by AbleSci AI